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Marina Alexeeva,‡ Espen Åberg,§ Richard A. Engh and Ulli Rothweiler*
Department of Chemistry, The Norwegian Structural Biology Centre, The Arctic University of Norway, 9037 Tromsø,
Norway. *Correspondence e-mail: ulli.rothweiler@uit.no
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a
protein kinase associated with neuronal development and brain physiology.
The DYRK kinases are very unusual with respect to the sequence of the catalytic
loop, in which the otherwise highly conserved arginine of the HRD motif is
replaced by a cysteine. This replacement, along with the proximity of a potential
disulfide-bridge partner from the activation segment, implies a potential for
redox control of DYRK family activities. Here, the crystal structure of DYRK1A
bound to PKC412 is reported, showing the formation of the disulfide bridge and
associated conformational changes of the activation loop. The DYRK kinases
represent emerging drug targets for several neurological diseases as well as
cancer. The observation of distinct activation states may impact strategies for
drug targeting. In addition, the characterization of PKC412 binding offers new
insights for DYRK inhibitor discovery.
1. Introduction
A substantial body of evidence indicates that dual-specificity
tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is
an important therapeutic target in neurological disorders,
including the scourges of Alzheimer’s disease (AD; Thies &
Bleiler, 2012), Parkinson’s disease (Kim et al., 2006) and
Huntington’s disease (Kang et al., 2005). The dyrk1a gene is
located in the Down syndrome critical region (DSCR) on
chromosome 21 (Guimerá et al., 1996), and full or partial
trisomy of DSCR in Down syndrome (DS) leads to over-
expression of DYRK1A. This is coupled to mental retardation
(Park et al., 2009), along with an Alzheimer’s-like dementia
(Teipel & Hampel, 2006) that appears relatively early in life
(compared with the occurrence of Alzheimer’s disease in the
general population). This occurs via several mechanisms (Liu
et al., 2008), one of which is the activity of DYRK1A to prime
the tau protein for further phosphorylation by GSK-3. This
leads to the hyperphosphorylation of tau, followed by self-
aggregation into neurofibrillary tangles, which are the primary
biomarker of AD (Woods et al., 2001). Further, DYRK1A
has recently been identified as a risk factor for AD, enabling
detection of the disease prior to the development of beha-
vioural symptoms by analyzing human plasma (Janel et al.,
2014).
Parallel to studies of the pathophysiological roles of
DYRK1A in neurological disorders, the structural mechan-
isms of DYRK catalysis and activation are coming under
increasing scrutiny. DYRK1A, along with its analogues from
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the evolutionarily conserved family of dual-specificity tyrosine
phosphorylation-regulated kinases (DYRKs), belongs to the
CMGC group in the human kinome (Manning et al., 2002).
The unique activity of the DYRKs, which gives the subgroup
its name, is the dual capability to phosphorylate not only
the serine/threonine residues within the consensus sequence
(RXS/TR; Becker et al., 1998) but also the second highly
conserved tyrosine residue located on the activation segment
in the YXY motif (Tyr321 in DYRK1A) during autoactivation
(Becker & Sippl, 2011). Initially, the tyrosine phosphorylation
was believed to be a one-time event that occurred during the
translation of DYRK in the ribosome; more recent studies,
however, have shown that DYRK1A is able to autophos-
phorylate other tyrosine residues and that it is not strictly
coupled to the translation event (Walte et al., 2013). The
DYRK family is divided into two subclasses, class 1 (DYRK1A
and DYRK1B) and class 2 (DYRK2, DYRK3 and DYRK4),
based on sequence identity and the presence of specific
sequence motifs (Becker et al., 1998). The members of the
DYRK family are regulators of diverse cellular processes,
including cell division, differentiation, survival and apoptosis
(Aranda et al., 2011). The two DYRK1 isoforms (DYRK1A
and DYRK1B) share 85% identity in the kinase domain.
There is only one residue difference within the ATP-binding
pocket, namely Met240 in DYRK1A versus Leu192 in
DYRK1B at the gatekeeper +2 site of the hinge region. The
role of DYRK1B has been investigated in myogenesis, and
represents an emerging therapeutic target in pancreatic and
ovarian cancers (Deng et al., 2003; Friedman, 2010, 2013).
Besides their unique dual phosphorylation specificity, the
DYRK kinases are distinguished by their idiosyncratic HCD
sequence in the catalytic loop, which is otherwise highly
conserved as HRD (Johnson et al., 1996). The position of
this cysteine creates the potential to form an intramolecular
disulfide bridge with a cysteine from the activation loop
(Soundararajan et al., 2013; Becker & Sippl, 2011). A
mechanistic role for such a disulfide bridge has not yet been
demonstrated. However, redox regulation of proteins,
including protein kinases, via the modification of cysteine
residues is an important regulatory process in cell signalling
(Eaton, 2006; Truong & Carroll, 2013). For example, the
formation of an intramolecular disulfide bridge (not involving
an HRD/HCD motif) in MKK6 and other MAP2Ks inacti-
vates them by blocking ATP binding (Diao et al., 2010).
The potential of DYRK1A as a drug target for DS, and
advances in DYRK1A inhibitor programs aiming to treat
cancer and Alzheimer’s disease, have been summarized in
recent reviews (Becker et al., 2014; Smith et al., 2012; Ionescu
et al., 2012). The inhibitors that have been crystallized in
complex with DYRK1A are small molecules in the range
200–600 Da and belong to the ATP-competitive type I kinase
inhibitors that bind to the active (DFG-in) conformation of
the kinase domain (Anderson et al., 2013; Ogawa et al., 2010;
Tahtouh et al., 2012).
In this paper, we report a new crystal structure of DYRK1A
in complex with the inhibitor PKC412, along with details
of the binding of PKC412 to DYRK1A as characterized by
stability and activity assays. PKC412 (midostaurin) is a deri-
vative of the broad-spectrum kinase inhibitor staurosporine,
an alkaloid isolated from Streptomyces staurosoreus (Omura
et al., 1977), and has previously been described as a selective
inhibitor of protein kinase C (PKC), VEGFR2, KIT, PDGFR
and FLT3 (Fabbro et al., 2000; Weisberg et al., 2002). PKC412
is under investigation as a treatment for acute myeloid
leukaemia (Fischer et al., 2010; Stone et al., 2012) and has been
in phase III clinical trials since 2008 (ClinicalTrials, 2014).
2. Materials and methods
2.1. Expression and purification
DYRK1A and DYRK1B constructs comprising the kinase
domain (DYRK1A, residues 126–490; DYRK1B, residues 78–
451) were cloned into pEXP17 plasmid with N-terminal 6His
affinity tags and TEV protease cleavage sites. The proteins
were expressed in shaker-flask cultures overnight at 17.8C
in TB medium. For the purification of DYRK1A, the cells
were resuspended in a lysis buffer consisting of 50 mM sodium
phosphate buffer pH 8.0 with 500 mM NaCl; for DYRK1B,
50 mM HEPES buffer pH 8.0, 50 mM KCl, 250 mM NaCl was
used. The bacteria were lysed by sonication in the presence of
0.5% Tween 20. Purification was performed using Ni–NTA
columns and an imidazole gradient (10–500 mM), followed by
cleavage with TEV protease overnight and a second Ni–NTA
column to separate the kinase from uncut protein and
protease. Final purification of DYRK1A was performed by
size-exclusion chromatography (SEC) in 50 mM MOPS pH
6.8, 50 mM KCl, 2 mM -mercaptoethanol and that of
DYRK1B was performed in 50 mM HEPES buffer pH 8.0,
50 mM KCl, 250 mM NaCl, 2 mM -mercaptoethanol.
2.2. Crystallization
Screening for crystallization was performed with DYRK1A
in 96-well sitting-drop plates, mixing 200 nl protein solution
with 200 nl precipitant solution. Commercially available
screens as well as in-house screens were used. An initial hit
was found in the JCSG-plus screen (Molecular Dimensions)
consisting of 0.2 M sodium thiocyanate, 20% PEG 3350. This
condition was further optimized and improved by an additive
screen with 96 conditions (Hampton Research), which
produced the final crystallization condition: 10–16% PEG
3350, 0.1 M potassium thiocyanate, 0.1 M KCl (or 0.1 M NaCl
or 0.1 M LiCl; other salts of alkali halides were also success-
fully used).
For co-crystallization with the inhibitor PKC412, the kinase
DYRK1A was concentrated to 7–10 mg ml1 in SEC buffer
and mixed with inhibitor solution in DMSO to achieve an
approximately threefold molar excess of inhibitor. The final
concentration of DMSO was 4%. The protein–inhibitor
mixture was then mixed in a 1:1 ratio with the crystallization
solution [100 mM potassium thiocyanate, 50–100 mM LiCl (or
NaCl or KCl), 10–16% PEG 3350] to give a final drop size of
4 ml. Crystallization was performed in 24-well hanging-drop
plates. Octahedron-shaped crystals appeared within 5–7 d at
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room temperature. Crystals were cryoprotected in crystal-
lization solution modified to include 30% ethylene glycol and
were flash-cooled in liquid nitrogen.
2.3. Structure solution and refinement
X-ray diffraction data were collected at the Helmholz
Zentrum Berlin (Berlin Electron Storage Ring Society for
Synchrotron BESSY II, Berlin, Germany). The images were
integrated using the XDSapp software (Krug et al., 2012)
provided by the Helmholz Zentrum Berlin. The resolution
cutoff chosen by the software is based on the CC1/2 (Evans,
2012; Karplus & Diederichs, 2012). The structure was solved
by molecular replacement with Phaser (McCoy et al., 2007)
using the DYRK1A structure with PDB code 3anq (Ogawa et
al., 2010) as a search model. Refinement was performed by
iterative cycles of PHENIX (Adams et al., 2010) and the CCP4
(Winn et al., 2011) program REFMAC5 (Murshudov et al.,
2011) followed by the manual refitting of residues into the
electron-density map using Coot v.0.7.2 (Emsley et al., 2010).
The cif file for PKC412 was generated by PRODRG (Schüt-
telkopf & van Aalten, 2004). Waters were placed by Coot
v.0.7.2 (Emsley et al., 2010). The crystallographic data and
model statistics are summarized in Table 1.
2.4. Thermal shift assay
20 ml 1 mg ml1 DYRK1A in SEC buffer was mixed with
5 ml SYPRO Orange solution and either 1 ml DMSO or inhi-
bitor (PKC412 or harmine; 10 mM) in DMSO was added.
Samples were heated from 10 to 90C in 0.3C steps and the
melting point was calculated from the slope of the melting
curve. Each experiment was performed as three replicates.
2.5. Activity assay
Determination of the enzyme activity, the Km value for
DYRK1A and DYRK1B and the inhibitory constants was
performed by an ATP-regenerative NADH-consuming assay
(Cook et al., 1982). The enzyme velocity was measured at
340 nm over a time period of 300 s at room temperature. ATP
and the peptide RRRFRPASPLRGPPK (DYRKtide) were
used as substrates. For determination of the Km, the reaction
mixture was composed of 75 ml 100 mM MOPS buffer pH 6.8,
10 mM KCl, 10 mM MgCl, 1 mM phosphoenolpyruvate, 1 mM
DYRKtide, 1 mM -mercaptoethanol, 15 units ml1 lactate
dehydrogenase, 10 units ml1 pyruvate kinase and 10.7 mM
NADH. 10 ml 5–20 mM DYRK1A or DYRK1B and 10 ml ATP
in the concentration range from 4 mM to 50 mM were added to
give a total volume of 95 ml. For determination of the Ki, the
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Table 1
Crystallographic data and model statistics.
Values in parentheses are for the final shell.
Data collection
Source Beamline 14.1, BESSY II
Detector Pilatus 6M
Wavelength (Å) 0.918
No. of crystals used 1
No. of frames 360
Oscillation range per frame () 0.5
Diffraction data
Space group P212121 [No. 19]
Unit-cell parameters (Å) a = 87.8, b = 87.9, c = 229.9
Protein molecules in asymmetric unit 4
No. of measurements 359740
Unique reflections 55625
Resolution range (Å) 48.3–2.6 (2.7–2.6)
Completeness (%) 99.7 (98.6)
Mosaicity () 0.2
hI/(I)i 9.1 (1.9)
Observed R factor (%) 16.7 (104)
CC1/2 99.4 (64.7)
Refinement
Resolution limits (Å) 48.3–2.6 (2.7–2.6)
No. of reflections used 52841
Reflections observed (%) 99.7
Free reflections (%) 5.0
No. of protein atoms 11036
No. of heterogen atoms 176
No. of waters 223
R factor (overall/free) (%) 20.8/24.8
Overall figure of merit 0.87









Overview of DYRK1A in complex with PKC412 (chain A) showing key
features. The PKC412 inhibitor is shown as red sticks. Stick representa-
tions also highlight Met240 of the hinge, the gatekeeper Phe238, the DFG
motif, the phosphotyrosine Tyr321 of the activation loop, its anchoring
arginines Arg328 and Arg325, and the disulfide bridge between Cys286
and Cys312.
reaction mixture was used as described above but a constant
concentration of 128 mM ATP was combined with 2 ml
PKC412 in DMSO at concentrations ranging from 4 nM to
20 mM to give a total volume of 97 ml. All measurements were
performed in triplicate at room temperature. The data were
analyzed using GraphPad Prism 6.
3. Results
3.1. Overall crystal structure
The crystal structure contains a tetramer as the asymmetric
unit, with the four individual DYRK1A molecules related to
each other by three perpendicular twofold rotation axes (as
previously described for PDB entries 3anq and 3anr; Ogawa et
al., 2010) and with the typical protein kinase fold also shared
by DYRK structures (Ogawa et al., 2010; Soundararajan et al.,
2013; Tahtouh et al., 2012; Anderson et al., 2013). Tyr321 in the
activation segment is phosphorylated in the structure (Fig. 1)
and is anchored to Arg325 and Arg328. The four individual
chains in the asymmetric unit are not identical; chain A has the
best fit to the electron density and is the most complete chain.
The three other chains show more disorder, especially in
the CMGC insert. Chain A lacks clear density in the loop
comprised of amino acids 409–412, chain B lacks density for
amino acids 213–218 and 407–414, chain C lacks density for
amino acids 408–412 and chain D lacks density for amino acids
408–414 and 437–444.
3.2. Binding of PKC412
Contours for PKC412 were clearly visible in the difference
electron-density map, and the fit is nearly unambiguous. One
partial exception is the phenyl-ring terminus, especially for
the inhibitor bound in chain C. PKC412 is bound in the ATP
pocket via two hydrogen bonds made by the amine and ketone
group in the 3-pyrroline-2-one head group of PKC412 to the
hinge amino acids Glu239 and Leu241. Owing to the lack of
any additional hydrogen acceptor or donor in the 3-pyrroline-
2-one head group, there can be no polar interaction with the
catalytic Lys188, in contrast to previous DYRK1A–inhibitor
structures (Ogawa et al., 2010), and the binding involves
mostly buried hydrophobic surfaces (Fig. 2a and Supplemen-
tary Fig. S1). The phenyl-ring extension of PKC412 emerges
from the ATP pocket, and has Glu291 as its closest neighbour
(3.3 Å); the next neighbours Asn244 and Tyr246 are at a
distance of greater than 5 Å. In contrast to staurosporine,
PKC412 does not have an NH group that could make a
stabilizing hydrogen bond to the carbonyl of Glu291, as seen,
for example, in the PKA–staurosporine structure with PDB
code 1stc (Glu170 in PKA numbering; Prade et al., 1997). Its
replacement, the benzoyl group, induces a rotamer shift that
places the methyl group at the position of the former
hydrogen bridge, displacing PKC412 upwards. On average,
PKC412 binds protein kinases more weakly than stauro-
sporine (Gani & Engh, 2010). The loss of this additional
hydrogen bridge is likely to be a contributor to this.
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Figure 2
(a) Binding of PKC412 to DYRK1A. Hydrogen bonds are shared by the backbone atoms of Glu239 and Leu241. However, most of the interactions are
via hydrophobic residues. The catalytic lysine (Lys188) does not participate in the binding of PKC412. (b) Overlay of different DYRK1A structures with
inhibitors: harmine (PDB entry 3anr, cyan), LDN-211898 (PDB entry 5aik, orange), DJM2005 (PDB entry 2vx3, grey) and PKC412 (PDB entry 4nct,
red).
One exception to the weaker binding of PKC412 compared
with staurosporine is observed for MAP3K3 (or MEKK3). It
binds PKC412 with a Kd of 210 nM, an increase of more than
tenfold over that for binding to staurosporine (Davis et al.,
2011). As no structure of the kinase domain of MAP3K3 has
been published, hypotheses for this increase remain spec-
ulative. If the binding data are correct, there may be no
penalty for the loss of a hydrogen bond as described above,
and in addition there must be MAP3K3-specific stabilizing
interactions, presumably with the phenyl group of PKC412.
The amino acids following the HRD (HCD in DYRK1A)
segment might play a role in stabilization of the phenyl group
of PKC412. Glu291 in DYRK1A (HCDLKPE291) corre-
sponds to an alanine in MAP3K3 (HRDIKGA493), which
would allow more space and possibly a different rotamer of
PKC412, which might further allow the carbonyl moiety of
PKC412 to form hydrogen-bonding interactions. This carbonyl
group is oriented towards solvent in DYRK1A. Other amino-
acid residues in MAP3K3 might directly interact with the
phenyl ring of PKC412, adding a stabilizing effect. This ring
has no rigidifying interactions in DYRK1A and is partially
disordered. However, homology models for MAP3K3
(ProteinModelPortal; http://www.proteinmodelportal.org/
query/uniprot/Q99759) do not identify any obvious candidates
for such interactions.
The main target for the therapeutic effects of PKC412 is
FLT3, to which PKC412 and staurosporine bind with a similar
high potency (Davis et al., 2011). One crystal structure is
available for FLT3 (PDB entry 1rjb; Griffith et al., 2004). This
is in a DFG-out conformation, in which the phenylalanine
would block the binding of PKC412 (or staurosporine) to the
ATP-binding pocket. Indeed, PKC412 binds to FLT3 in its
active conformation (as, for example, necessary to explain
the pattern of resistance mutations that occur in FLT3; von
Bubnoff et al., 2009). However, as with MAP3K3 above, the
identification of key structural features of FLT3 that would
anomalously leave it unaffected by the factors that make
PKC412 a weaker inhibitor compared with staurosporine for
the majority of the kinases are not possible without further
experimental information.
Several structures of DYRK1A with inhibitors have been
published. An overlay of PKC412 (red) with harmine (PDB
entry 3anr, cyan; Ogawa et al., 2010), DJM2005 (PDB entry
2vx3, grey; Soundararajan et al., 2013) and LDN-211898 (PDB
entry 5aik, orange; J. M. Elkins, M. Soundararajan, J. R. C.
Muniz, G. Cuny, J. Higgins, A. Edwards, C. Bountra & S.
Knapp, unpublished work) (Fig. 2b) shows that the ATP-
binding pockets are identical with the different inhibitors
bound with one exception: the inhibitor DJM2005 induces a
rotamer change for Phe170 of the glycine-rich loop. Although
the inhibitors occupy roughly the same volumes, the additional
hydrogen bonds of harmine and LDN-211898 to Lys188 are
associated with deeper penetration into the ATP-binding
pocket compared with PKC412 and DJM2005 (Fig. 2b). All of
the inhibitors make hydrogen bonds to the hinge and the
backbone carbonyl or amide groups of Glu239, Met240 and/or
Leu241.
3.3. Disulfide bridge
A major distinguishing feature of the structure described
here (PDB entry 4nct) is the disulfide bridge formed between
Cys286 of the HCD motif in the catalytic loop and Cys312 in
the activation segment (Supplementary Figs. S2 and S3). This
disulfide bridge is present in all four monomers of the asym-
metric unit. The distances between the two cysteine S atoms
after refinement in chains A, B, C and D (without bond
restraints) are at ideal distances for disulfide bridges (on
average 2.1 Å). The previously published structure with
PDB code 2vx3 (Soundararajan et al., 2013), with a reduced
configuration, has a cysteine–cysteine distance of 4.3 Å
(Supplementary Fig. S3). Chain D in our structure has some
unmodelled difference density around Cys312. It is plausible
that chain D exists in mixed partial occupancy states whereby
a minor fraction of the D chains have a reduced configuration.
The formation of the disulfide bridge does not cause any large-
scale changes in the overall arrangement of the structure, as
shown by a superposition of chain A of our structure (PDB
entry 4nct) with chain A from PDB entries 2vx3 and 3anq.
However, it locks the N-terminal portion of the activation
segment into a more rigid conformation, displacing residue
Cys312 towards the catalytic motif HCD (Fig. 3). The rest of
the activation loop is folded differently but is most likely to
adopt multiple conformations, which in turn are likely to be
influenced by the crystal packing. The DYRK1A structures
complexed with INDY and harmine (PDB entries 3anq and
3anr), which have the same crystal packing (space group 19;
P212121) as PDB entry 4nct also have almost identical loop
conformations after Cys312. However, details of the local fold
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Figure 3
The structure reported here of DYRK1A (PDB entry 4nct) in complex
with PKC412 (green) is superimposed with the published DYRK1A
structures with PDB codes 2vx3 (grey) and 3anq (turquoise). The box
highlights the disulfide bridge formed between Cys286 and Cys312 in
DYRK1A in complex with PKC412 (green), which is absent in the 2vx3
and 3anq structures.
around Cys312 differ compared with PDB entry 4nct, as the
two previously published structures lack the disulfide bridge.
The HCD motif is rather rigid in the DYRK1A structure
and is not significantly displaced upon disulfide-bridge
formation (compared with the previously described struc-
tures). In contrast, the DFG motif and subsequent residues are
displaced by 1–2 Å, with Cys312 moving most (almost 3 Å).
In addition, the main-chain dihedrals between Ser311 and
Cys312 change significantly (Fig. 4). Besides the displacement
of activation-loop residues, formation of the disulfide induces
changes in the local hydrogen-bonding network of the
catalytic loop residues I283IHCD287 and the activation-loop
residues D307FGSSCQ313. The hydrogen bond between the
backbone carbonyl of Ile284 and the backbone amide of
Cys312 is weakened, and increases in length from 3.1 to 3.4 Å
(Fig. 4). Analogously, the hydrogen bond between the back-
bone amide of Ile284 and the backbone carbonyl of Cys312 is
lengthened by 20% from 2.8 to 3.3 Å. The hydrogen bond
between the side-chain OH of Ser311 and the carbonyl of
His285 remains largely unchanged.
The HCD motif in the catalytic loop in DYRK kinases
is rare in the human kinome. Besides the DYRK family, a
cysteine in this position is found in only a few other kinases:
the PKD family and the tyrosine-protein kinases SgK269,
ULK4 and LRRK1 (ULK4 and LRRK1 have an FCD motif).
Of these kinases, only UKL4 has a potential partner cysteine
in the activation segment (between the DFG and APE motifs).
The PKD kinases have no cysteine in the activation segment
but they share a cysteine immediately preceding DFG,
resulting in a conserved CDFG motif. However, any disulfide-
bridge formation between this cysteine and other cysteines
within the kinase domain would require additional reorgani-
zation of the fold.
3.4. Binding studies: thermal shift experiments
To further characterize the crystal structure, we tested the
inhibition and binding of PKC412 in vitro. Thermal stabiliza-
tion of a native protein upon ligand binding is a fast and robust
way to screen for inhibitors, since the stabilizing effect of a
compound upon binding can, to a first approximation, be
proportional to the affinity and inhibitor concentration
(Fedorov et al., 2012). A thermal shift assay was performed to
test the effect of PKC412 binding on the stability of DYRK1A
undergoing thermal denaturation. Three parallel denaturation
experiments were performed: DYRK1A in buffer, with
DMSO and with PKC412 dissolved in DMSO. As a positive
control, the published inhibitor harmine was used at the same
concentration in DMSO. The results are summarized in
Table 2. The melting point for DYRK1A in buffer was 51C.
The addition of DMSO did not have any effect on the melting
temperature, whereas the presence of PKC412 increased
the melting point by 2C. Interestingly, the smaller inhibitor
harmine increased the melting temperature by around 6C.
PKC412 only forms hydrogen bonds at the hinge region,
whereas harmine forms one hydrogen bond at the hinge and
one to the catalytic Lys188 (Ogawa et al., 2010). The binding
of PKC412 is more predominantly hydrophobic in character.
In addition, harmine is much more soluble in water than
PKC412. Since the stabilizing effect of a compound is
dependent on the extent of binding, and therefore on the
concentration of the compound, the low solubility and
therefore concentration of PKC412 in water could be the
reason for the lower stabilizing effect compared with harmine.
Although these approximations of linear dependence are
observed to be valid in many cases, exceptions include
destabilization upon (i.e. despite) binding, and the values for
the thermal shifts must be interpreted with caution (Cimm-
perman et al., 2008).
3.5. Activity assay: DYRK1A versus DYRK1B
PKC412 was further tested for its ability to inhibit the
kinase activity of DYRK1A and DYRK1B in vitro. DYRK1B
is the closest homologue of DYRK1A, with a sequence
identity of about 85% for the kinase domain. An ATP-
regenerative, NADH-consuming assay for kinases (Cook et
al., 1982) was used to determine the substrate-dependent
research papers
1212 Alexeeva et al.  DYRK1A–PKC412 complex Acta Cryst. (2015). D71, 1207–1215
Figure 4
Superposition of chain A of PDB entry 4nct (green) with chain A of PDB
entry 2vx3 (grey) showing the hydrogen-bond network between the
catalytic loop and the activation loop. Formation of the disulfide bridge
weakens the hydrogen interactions. The main change is the displacement
of Cys312 and the neighbouring residues (Ser310–Gln313), while Cys286
and the HCD motif remain largely unchanged.
Table 2
Thermal shift experiments with DYRK1A and the inhibitors PKC412 and
harmine.







Km and Vmax from the kinetic assay.
Km(ATP) (mM) Vmax (AU s
1)
DYRK1A 118.5  7.8 51.5  1.0
DYRK1B 80.7  2.7 100.7  0.9
Michaelis–Menten constants for the kinase domains of
DYRK1A and DYRK1B. The 15-residue peptide DYRKtide
(RRRFRPASPLRGPPK) was used as a substrate for
DYRK1A/B. The experiments were performed at room
temperature in triplicate for a series of dilutions of ATP in
the range from 50 mM to 4 mM (Fig. 5). The results of the Km
determination are summarized in Table 3. The Km values for
DYRK1A and DYRK1B are 118 and 80 mM, respectively, thus
showing DYRK1B to have a somewhat stronger affinity for
ATP in this assay and under these conditions. The Km value
for DYRK1A measured in the Cook assay is higher compared
with the published value of 35 mM determined by a radio-
metric method (Himpel et al., 2000). However, since the assay
itself and the conditions, including temperature, substrate and
kinase (full length versus kinase domain) used to determine
the Km values are different, differences are not unexpected.
Km values are sensitive to the specific assay conditions and Km
values for a single kinase do show variations (typically within a
factor of five or less) when measured under different condi-
tions (Knight & Shokat, 2005).
The Cook assay was used to quantify PKC412 inhibition of
DYRK1A and DYRK1B (Fig. 6). PKC412 inhibits DYRK1A
with an IC50 of 59 nM (at a constant ATP concentration of
128 mM), corresponding to a Ki of 28 nM [Km(ATP) = 118 mM].
PKC412 inhibits DYRK1B with a similar strength: the
measured IC50 was 66 nM (at 128 mM ATP), with a resultant
Ki of 25 nM [Km(ATP) = 80 mM]. These values are summarized
in Table 4. For comparison, the Ki values determined under
these assay conditions for harmine for DYRK1A and
DYRK1B are 120 and 340 nM, respectively.
Under these assay conditions, PKC412 is thus equipotent
against DYRK1A and DYRK1B. These DYRKtide phos-
phorylation assay results differ considerably from the Kd
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Figure 6
Dose–response curves for the inhibitor PKC412.
Figure 5
Michaelis–Menten plots to determine the Km values for ATP. The concentration of the enzyme and the second substrate peptide DYRKtide were kept
constant.
Table 4
IC50 and Ki values for PKC412 inhibition of DYRK1A and DYRK1B.
Kinase ATP (mM) IC50 (nM) Ki (nM)
DYRK1A 128 59 28.4
DYRK1B 128 66 25.4
values published previously (Davis et al., 2011). However,
those values were determined in the absence of peptide
substrate using different assay conditions. The relatively small
differences between the affinities of PKC412 for DYRK1A
versus DYRK1B are consistent with the fact that the two
kinases differ by only one residue in the ATP pocket, namely
methionine and leucine in DYRK1A and DYRK1B, respec-
tively, at the gatekeeper +2 position at the hinge.
4. Discussion
One phenomenon that reflects alterations in the cellular redox
environment is the extent of reversible modification of the
thiol group in cysteine side chains (Groitl & Jakob, 2014).
Redox-sensitive proteins play roles in all kinds of cellular
signalling processes and include a growing list of protein
kinases such as PDGFR, EGFR, IRK, FGFR, JAK, PKB,
PKC, PKG, ASK1, MEKK1, MKK6, p38, c-Src, LYN, IKK,
ATM and PKM2 (Giorgi et al., 2010; Corcoran & Cotter, 2013;
Truong & Carroll, 2013). Some of these proteins undergo
reversible disulfide-bond formation in response to the redox
status of the cell, which may alter signalling to rapidly adapt
cellular processes. The disulfide bridge in DYRK kinases
involves a cysteine located at a position in the catalytic loop
which is otherwise highly conserved among protein kinases
as an arginine. Johnson and coworkers defined the term ‘RD
kinase’ after they observed that all kinases regulated through
activation-loop phosphorylation have a conserved arginine
immediately preceding the conserved catalytic aspartate in the
HRDLKxxN (or HRD) motif of the catalytic loop (Johnson
et al., 1996). The HRD arginine anchors the phosphate group
of the primary phosphorylation site of the activation loop,
stabilizing it in an active conformation (Nolen et al., 2004). The
location of Cys286 as a substitution for the HRD arginine is a
rare but distinguishing feature of DYRK-family kinases. Both
Cys286 and Cys312 are located in positions corresponding
to the RD pocket. It is reasonable to hypothesize that the
cysteines in such a strategic location can act as a redox-
sensitive switch, much as RD kinases (ex ERKs) are regulated
by an electrostatic phosphorylation switch. Others have
previously proposed redox regulation as a potential mode of
regulation for DYRK family kinases (Becker & Joost, 1999;
Becker & Sippl, 2011; Kannan & Neuwald, 2004). Becker and
Sippl pointed out that the thiol moieties of these cysteines
were sufficiently close (4.3 Å in DYRK1A and DYRK2)
to allow the formation of a disulfide bridge. They further
speculated that the potential switch between —SH reduced
and —S—S— oxidized states could result in a conformational
change and altered catalytic activity of DYRK kinases (Becker
& Sippl, 2011). This followed an earlier proposal based on
homology modeling that the formation of a disulfide bond
between Cys286 and Cys312 might stabilize the activation loop
(Kannan & Neuwald, 2004). The structure that we present in
this work confirms the occurrence of this disulfide bond and
demonstrates a role in the stabilization of the activation
segment: the covalent disulfide bond holds the activation loop
near the catalytic loop in a conformation altered relative to
that of the unbound activation loop. Thus, one function of
DYRK1A (and the other DYRK family members) might be
to sense the presence of reactive oxygen species (ROS): an
increasingly oxidizing environment would induce the forma-
tion of the disulfide bridge and trigger a signalling response. In
this context, it is interesting to note that DYRK1B (the closest
related kinase to DYRK1A) plays a role in the regulation of
ROS levels. In quiescent cultures of pancreatic SU86.86 and
Panc1 cancer cells, DYRK1B reduced the levels of ROS by
increasing the transcription of the antioxidant genes ferrox-
idase, superoxide dismutase SOD2 and SOD3 (Deng et al.,
2009, 2014).
PKC412 (midostaurin) is in phase III clinical trials to treat
acute myeloid leukaemia; a possible application in neurolo-
gical disease has not been established. However, the structure
of DYRK1A–PKC412, together with characterization of the
binding, may aid in the consideration of alternate uses of
PKC412 or its derivatives in which DYRK kinases represent
the main target or targets. Potentially relevant diseases for
such expanded applications include neurological diseases such
as Alzheimer’s or Down syndrome.
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